Hospitals building or expanding an interventional program for deep vein thrombosis face a structured thrombectomy device evaluation process that goes well beyond simply comparing headline clinical outcomes between competing systems. Budget structure, staffing implications, case mix, and long-term supplier relationships all shape which platform actually fits a given institution's needs. This guide walks through the main criteria hospitals typically weigh.
Capital vs. Disposable Cost Structure
Thrombectomy systems generally fall along a spectrum from purely disposable, single-use catheters requiring no dedicated capital equipment, to systems that pair a reusable console or pump with disposable catheter components. Purely disposable systems may lower the barrier to adoption since there is no upfront capital purchase, while console-based systems may offer lower per-case disposable costs over time but require an initial capital investment and ongoing maintenance considerations. Hospitals typically model total cost of ownership across a realistic case volume rather than comparing sticker price alone.
Matching Device Capability to Case Mix
A program that regularly encounters a wide range of clot presentations — from smaller distal DVT to extensive iliofemoral occlusion — may benefit from a platform offering multiple device types or adjustable settings that can address this variability without requiring a completely different system for edge cases. Reviewing recent case history and anticipated future volume helps procurement teams estimate whether a narrower or broader device portfolio best serves the institution.
Training, Support, and Learning Curve
Interventional teams adopting a new thrombectomy system require adequate training and ongoing clinical support, particularly during the initial period of use. Evaluating a manufacturer's ability to provide hands-on training, responsive technical support, and case-planning assistance is a meaningful part of the overall assessment, since a device with strong theoretical capability but poor support infrastructure may not translate into consistent clinical performance for a new user team.
Regulatory and Quality Assurance Documentation
Procurement and value analysis committees typically require documentation confirming CE marking under EU MDR 2017/745 (or equivalent regulatory clearance relevant to the purchasing region) and manufacturing under ISO 13485 quality standards before a device can be formally adopted. Requesting and reviewing this documentation early in the evaluation process helps avoid delays later in the procurement cycle.
Considering INVAMED's Portfolio
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Building Consensus Across Stakeholders
A thorough evaluation typically involves input from interventional radiologists or vascular surgeons who will use the device clinically, nursing staff managing peri-procedural care, and finance or supply chain teams managing budget and contracting. Aligning these stakeholders around shared evaluation criteria, rather than allowing the decision to rest solely on clinical preference or cost alone, tends to produce a more sustainable long-term procurement outcome.
What documentation should a hospital request before finalizing a purchase?
Hospitals should request current CE marking documentation under EU MDR 2017/745, evidence of ISO 13485 manufacturing certification, and the device's Instructions for Use (IFU), which together confirm regulatory compliance and appropriate indications for use.